Darwinweg 24
Leiden 2333 CR
Netherlands
31 71 524 7400
https://www.pharming.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 332
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Sijmen de Vries M.B.A., M.D. | Pres, CEO & Exec. Director | 1,18M | N/D | 1959 |
Mr. Jeroen Wakkerman | Chief Financial Officer | N/D | N/D | 1969 |
Ms. Mireille Sanders M.Sc. | Chief Operations Officer | N/D | N/D | 1968 |
Susanne Embleton | Investor Relations Mang. | N/D | N/D | N/D |
Mr. Ruud Van Outersterp | Chief Ethics & Compliance Officer | N/D | N/D | 1964 |
Dr. Anurag Relan M.D., MPH | Chief Medical Officer | N/D | N/D | 1972 |
Mr. Stephen Toor | Chief Commercial Officer & GM Americas | N/D | N/D | 1971 |
Dr. Alexander Breidenbach M.B.A. | Chief Bus. Officer | N/D | N/D | N/D |
Dr. Bruno M. L. Giannetti | Consultant | N/D | N/D | 1952 |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
L'ISS Governance QualityScore di Pharming Group N.V. al 1 ottobre 2023 è 4. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 1; diritti degli azionisti: 4; retribuzione: 8.